Value
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.4 |
| P/S | 8.4 |
| EV/EBITDA | 6.0 |
| Fwd P/E | 9.1 |
| PEG | 9.2 |
| Analyst target | 3.0 |
- ▸Forward P/E: 11.6x
- ▸PEG: 0.64
- ▸Attractively valued
PRI · Why this verdict
Why Primerica (PRI) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Primerica is an exceptionally high-quality life insurance compounder with a 4-for-4 earnings beat streak and a 32% return on equity, though the stock has already reached its price target and near-term upside is limited by reinsurance concentration risk covering 90% of mortality exposure.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Ninety percent of Primerica's mortality risk is ceded to a very limited number of reinsurance counterparties, creating a structural vulnerability that could impair profitability if a counterparty fails or renegotiates terms. Bear case | No reinsurance counterparty disruption materializes and concentration risk remains at current levels rather than worsening over 12 months. | →Stable |
| CounterThe reinsurance structure has presumably been in place for years and may represent an industry-standard arrangement rather than a near-term credit risk. | ||
The company generates free cash flow equal to 139% of net income and earns a 32% return on equity, placing it among the highest-quality businesses in the life insurance sector with a recognized wide economic moat. Quality breakdown | Return on equity remains above 25% and free cash flow conversion stays above 100% of net income over the next year. | →Stable |
| CounterMargin compression from rising mortality claims or reinsurance cost increases could erode the high-quality financial profile that justifies the premium. | ||
Primerica has beaten earnings estimates in all 4 of the last 4 quarters with an average surprise of 9.2%, and its Piotroski F-Score of 9/9 reflects a business with consistent fundamental improvement. Earnings | Quarterly earnings surprises remain above 5% and the Piotroski score stays at 8 or higher over the next 12 months. | ↑Improving |
| CounterA single quarter of earnings disappointment could reset sentiment sharply given that the stock is already priced at or above analyst targets. | ||
The stock at $280.64 has already exceeded its analyst price target of $279.16, leaving negative upside of approximately 7.5% and triggering an asymmetry gate failure that removes the entry edge. Warnings | Analyst price targets are revised upward by at least 10% over the next 12 months to re-establish a positive reward-to-risk ratio. | →Stable |
| CounterAnalyst targets have consistently lagged the stock's actual performance given the perfect beat streak, and upgrades may follow quickly after the next earnings report. | ||
Ninety percent of Primerica's mortality risk is ceded to a very limited number of reinsurance counterparties, creating a structural vulnerability that could impair profitability if a counterparty fails or renegotiates terms.
→StableBear case
- Expectation
- No reinsurance counterparty disruption materializes and concentration risk remains at current levels rather than worsening over 12 months.
CounterThe reinsurance structure has presumably been in place for years and may represent an industry-standard arrangement rather than a near-term credit risk.
The company generates free cash flow equal to 139% of net income and earns a 32% return on equity, placing it among the highest-quality businesses in the life insurance sector with a recognized wide economic moat.
→StableQuality breakdown
- Expectation
- Return on equity remains above 25% and free cash flow conversion stays above 100% of net income over the next year.
CounterMargin compression from rising mortality claims or reinsurance cost increases could erode the high-quality financial profile that justifies the premium.
Primerica has beaten earnings estimates in all 4 of the last 4 quarters with an average surprise of 9.2%, and its Piotroski F-Score of 9/9 reflects a business with consistent fundamental improvement.
↑ImprovingEarnings
- Expectation
- Quarterly earnings surprises remain above 5% and the Piotroski score stays at 8 or higher over the next 12 months.
CounterA single quarter of earnings disappointment could reset sentiment sharply given that the stock is already priced at or above analyst targets.
The stock at $280.64 has already exceeded its analyst price target of $279.16, leaving negative upside of approximately 7.5% and triggering an asymmetry gate failure that removes the entry edge.
→StableWarnings
- Expectation
- Analyst price targets are revised upward by at least 10% over the next 12 months to re-establish a positive reward-to-risk ratio.
CounterAnalyst targets have consistently lagged the stock's actual performance given the perfect beat streak, and upgrades may follow quickly after the next earnings report.
Per-dimension breakdown
Quality
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 3.1 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.4 |
| FCF quality | 9.6 |
| Moat | 7.6 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 32%
- ▸Strong margins: 23%
- ▸Excellent cash conversion: 139% FCF/NI
- ▸Wide economic moat
Growth
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.5 |
| EPS growth | 5.6 |
Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.5 |
- ▸Overbought (RSI 75)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.6 |
| Price target | 4.7 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $924,086 (0.010% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.2 |
| quality rank | 8.8 |
| growth rank | 4.4 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.5 |
| support resistance | 2.1 |
| 52w position | 9.5 |
Risk (lower is worse)
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.5 |
| days to cover | 5.5 |
| volatility | 7.6 |
| beta | 7.7 |
| debt equity | 6.6 |
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.0 |
| dividend safety | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend aristocrat: 1.4% yield
How the verdict was assembled
Engine trigger
Wide-moat business. Accumulate on weakness.
Engine technical detail
verdict_path:
L4:PATH_E_WIDE_MOAT|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:15d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.5=NEGATIVE
Warning (0)
none
Reward-to-Risk
-1.52
Upside
-15.0%
Downside
9.9%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 15d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The STRONG_BUY_WAIT verdict reflects the ASYMMETRY gate's -1.5=NEGATIVE outcome against Quality at 8.5 and asymmetric R:R of -1.52.
The strongest dimensions are Quality at 8.5, Value at 7.3, and Insider at 7.3; the weakest are Technical at 4.7, Peer rank at 5.0, and Growth at 5.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -1.52 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Compounding Quality
Trip ifQuarterly earnings surprise falls below 0% in at least 2 of the next 4 quarters.
- P2Capital Efficiency Wide Moat
Trip ifReturn on equity drops below 20% in any reported fiscal year.
- P3Reinsurance Concentration Risk
Trip ifReinsurance counterparty exposure rises above 95% of mortality risk or a counterparty downgrade to below investment grade is disclosed.
- P4Target Exhaustion Limited Upside
Trip ifAnalyst consensus price target rises above $310 within 12 months, restoring at least 10% upside from current levels.